Pergamon

Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 16, pp. 2019-2024, 1996

0960-894X/96 $15.00 + 0.00

PII: S0960-894X(96)00359-9

SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ALKOXY SUBSTITUTED TRINEMS. PART I

Daniele Andreotti*, Stefano Biondi, Romano Di Fabio, Daniele Donati, Elisabetta Piga, Tino Rossi

Glaxo Wellcome S.p.A., Medicines Research Centre
**Fax +39-45-9218196, e-mail DGA9946@ggr.co.uk*
Via A. Fleming 4, 37138 Verona, Italy

Abstract. Synthesis of new 4-alkoxy substituted trinems **4**, **5**, **6**, **7** and **8** together with their antibacterial profiles compared to imipenem and GV104326 (**2**) are described. The good antibacterial profile observed for derivatives **4-7** encouraged further exploration of these derivatives.

The intense interest in the study of β-lactam antibiotics has led, in the last fifteen years, to the continue introduction of new classes of compounds[1] endowed with a broad spectrum of activity associated with very low toxicity levels which ensure them an outstanding role in antibacterial chemotherapy.

Fig.1



1



2, GV104326, R = Na
3, GV118819, R = $CH(CH_3)OCOOC_6H_{11}$

4, R = OMe
5, R = OH
6, R = CN
7, R = F





8

Some years ago, we at Glaxo[2] have identified a novel class of tricyclic β-lactam antibiotics, trinems (**1**, Fig. 1), formerly referred to as tribactams, which are characterised by high potency, high stability to both most relevant β-lactamases and to renal dehydropeptidases, associated with a good chemical stability. As a result GV104326, (**2**, Fig.1), and its metabolically labile ester GV118819 (**3**, Fig.1) were selected for development and are currently in phase II clinical trials.

Scheme 1



a) LHMDA, -78°C, THF; b) Pd/Al_2O_3, H_2 4.5 atm., EtOH; c) TEA, $ClCOCOOCH_2CH{=}CH_2$, CH_2Cl_2; d) $P(OEt)_3$, xylene, 120-140°C; e) TBAF, AcOH, THF; f) $Pd(PPh_3)_4$, potassium 2-ethylhexanoate.

With the aim to investigate biological properties of others 4-alkoxy derivatives, the synthesis of a series of analogues of **2** was undertaken in our laboratories, and this paper describes the synthesis and the preliminary antibacterial profile of compounds **4-8** (Fig. 1).

Trinems **4** and **8** have been prepared according to the procedure[3] utilised for compounds **2**, as outlined in Scheme 1. 2-(Methoxyethoxy)-cyclohex-2-en-1-one[4] **9** was reacted with commercially available

(+)-(3*R*,4*R*,1'*R*)-4-Acetoxy-3-[1'-(*tert*-butyldimethylsilyl)oxy]-ethyl]-2-azetidinone (**10**)[5] using LHMDA as base at -78°C in anhydrous THF yielding an inseparable 3:7 mixture of diasteroisomers **11** and **12** which was purified by flash chromatography in 52% overall yield.

During our attempts of double bond hydrogenation a number of catalysts as well as various reaction conditions were tried. Hydrogenation of the above mentioned mixture was found to give the best result using Pd/Al_2O_3 as catalyst, and separation by flash chromatography gave isomers **13**, **14** and **15** in 5, 11 and 35% yield respectively from **10**. Both azetidinones **13** and **15** were progressed to the corresponding trinems **4** and **8**, through intramolecular cyclisation of the corresponding oxalimide derivatives in the presence of $P(OEt)_3$ (Scheme 1)[6]. Oxalimides were obtained according to well estabilished procedures[6] and were used without any purification.

Scheme 2



a) R = OH, $HOCH_2CH_2OH$ as solvent and pTSA 10 % as catalyst; b) R = F, $HOCH_2CH_2F$ as solvent; c) R = CN, $HOCH_2CH_2CN$ as solvent and 0.25 eq of CAN; d) TBSCl, Imidazole DMF; e) i) DMSO, $(COCl)_2$, CH_2Cl_2, -78°C; ii) TEA, f) TEA, $ClCOCOOCH_2CH{=}CH_2$, CH_2Cl_2; g) $P(OEt)_3$, xylene, 120-140°C; h) TBAF, AcOH, THF; i) $Pd(PPh_3)_4$, potassium 2-ethylhexanoate.

Previous works[7] have shown that trinems with absolute configuration 8*S*,4*R* are generally the most promising isomers in terms of both antibacterial profile and biological stability. This prompted us to define a new and stereoselective route[8] for the synthesis of relevant compounds. The epoxide **17**, previously utilised in the synthesis of **2**[8], was therefore selected as a key intermediate in the preparation of 4-alkoxy trinems **5**, **6** and **7** as shown in Scheme 2.

When the epoxide ring of intermediate **17** was regioselectively opened, using ethylene glycol and dichloromethane 20:1 as solvent in the presence of catalytic amount of pTSA, the alcohol **18** was obtained and then directly converted into the corresponding silylated compound **19** using TBSCl and imidazole in dimethylformamide as solvent (75% overall yield from **17**). However, the same opening reaction using 3-hydroxyproprionitrile as solvent gave the desired product **21** in very low yield, which increased to 20% by using CAN[9] instead of pTSA as acidic catalyst.

Finally, in the case of 2-fluoroethanol as solvent, the epoxide **17** was opened in the absence of catalyst to give the desired product **20** in moderate yield (21%).

Oxidation of secondary alcohols **19**, **20** and **21** under Swern conditions (Scheme 2) provided the corresponding ketones **22, 23** and **24** in good yields. Their conversion into the corresponding trinems **5, 6** and **7** was achieved by the same procedure reported in Scheme 1.

The absolute stereochemistry of the final compounds was confirmed by spectroscopic studies and a more detailed description will be reported elsewhere.

The antibacterial activities of **4, 5, 6, 7** and **8** tested against several bacterial strains[10] are reported in Tab. 1 confirming the superior overall good antibacterial profile of the trinem class with *S* absolute configuration at position C-8 (compare **8** to **4**).

Table 1. *In vitro* antibacterial activity of trinems **4, 5, 6, 7** and **8** compared to Imipenem and **2**,

MIC (μg/ml)

	S.aureus 853	*S.pneumoniae* 3512	*E.faecalis* 850	*E.coli* 1850	*E.coli* 1919	*P.aeruginosa* 1911	*C.perfringens* 615	*B.fragilis* 2017
Imipenem	**0.1**	**<=0.01**	**2**	**0.5**	**0.5**	**4**	**0.03**	**0.06**
2	**0.2**	**<=0.01**	**1**	**0.5**	**0.5**	**>32**	**0.03**	**0.06**
4	**0.5**	**0.2**	**2**	**2**	**0.5**	**>32**	**0.03**	**0.1**
5	**0.5**	**0.1**	**8**	**0.5**	**0.5**	**>32**	**0.06**	**0.1**
6	**0.5**	**0.06**	**2**	**4**	**1**	**>32**	**0.03**	**0.2**
7	**0.2**	**0.03**	**4**	**4**	**0.5**	**>32**	**<=0.01**	**0.2**
8	**8**	**8**	**>32**	**>32**	**32**	**>32**	**>32**	**32**

***S. aureus* 853** = *Staphylococcus aureus* 853E, Penicillinase (PC1) producing strain; ***S. pneumoniae* 3512** = *Streptococcus pneumoniae 3512*; ***E. faecalis* 850** = *Enterobacter faecalis* 850; ***E. coli* 1850** = *Escherichia coli* 1850E; ***E. coli* 1919** = *Escherichia coli* 1919, β-lactamase producing strain (TEM 1) with permeable outer membrane; ***P.aeruginosa* 1911** = *Pseudomonas aeruginosa* 1911; ***C. perfringens* 615** = *Clostridium perfringens* 615E; ***B. fragilis* 2017** = *Bacteroides fragilis* 2017.

Compounds **4-7** have shown a good activity against Gram-positives anaerobes and aerobes and Gram-negative anaerobes but moderate activity Gram-negative aerobes. It is worth highlighting that trinems **4-8** have been proven to be notably more stable to DHP-I enzyme than Imipenem.

In conclusion, the described chemical modifications made on the remote position of alkoxy side chain of **2**, demonstrated promising antibacterial profile confirming the need for further and more detailed studies on this class of compounds.

Acknowledgements

We would like to thank the Analytical Department for their support and in particular Dr. M. Hamdan and Dr. C. Marchioro for providing spectroscopic data, we are also deeply indebted with Dr. E DiModugno for the antibacterial evaluation of the above reported compounds. Finally, we wish to thank Prof. G. Tarzia and Dr. A. D. Perboni for their helpful discussions throughout the duration of this project.

References and notes

1) a) Morin, R.B.; Gorman, M. *Chemistry and Biology of β-Lactam Antibiotics*; Ed.; Academic Press: New York, **1982**. b) Durckheimer, W.; Blumbach, J.; Lattrell, R.; Scheunemann, K.H. *Angew. Chem. Int. Ed. Engl.* **1985**, *24*, 180. c) Luckas, G.; Ohno, M. *Recent Progress in the Chemical Synthesis of Antibiotics*; Eds.; Springer Verlag: Berlin-Heidelberg, **1990**.

2) a) Tamburini, B.; Perboni, A.D.; Rossi, T.; Donati, D.; Andreotti, D.; Gaviraghi, G.; Carlesso, R. and Bismara, C. *Eur. Pat. Appl.* 416,953 (C07D477/00), March 13, **1991**. b) Tamburini, B.; Perboni, A.D.; Donati, D.; Andreotti, D.; Biondi, S.; Bismara, C. *Eur. Pat. Appl.* 416,952 (C07F7/18), **1991**.

3) Andreotti, D.; Rossi, T.; Marchioro, C.; Donati, D.; Perboni, A.D.; Di Modugno, E. *Bioorganic and Medicinal Chemistry Letters*, **1996**, *4*, 491.

4) 2-(Methoxyethoxy)-cyclohex-2-en-1-one was prepared refluxing for 16 hr a mixture of 2-methoxyethanol and 1,2-cyclohexanedione in toluene using Dowex resin as catalyst, purification by chromatography on alumina gave the desired keton in 35 % yield.

5) (+)-(3*R*,4*R*,1'*R*)-4-Acetoxy-3-[1'-(*tert*-butyldimethylsilyl)oxy]-ethyl]-2-azetidinone (**10**) is commercially available from Aldrich Chemical Company Inc, Milwaukee, WI

6) a) Battistini, C.; Scarafile, C.; Foglio, M.; Franceschi, G. *Tetrahedron Lett.* **1984**, *25*, 2395. b) Perrone, E.; Alpegiani, M.; Bedeschi, A.; Giudici, F.; Franceschi, G. *Tetrahedron Lett.* **1984**, *25*, 2399. c) *Protective Groups in Organic Chemistry*, McOmie J. F. W. ed.; Plenum Press, **1973**. d) Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, **1991**, Wiley Interscience, New York. e) Johnston, D. B. R.; Schmidt, S. M.; Bouffard, F. A.; Christensen, B. G. *J. Am. Chem. Soc.* **1978**, *100*, 313.

7) The Proceeding of the First International Symposium; Cambridge, England, 5-8th July 1992. Perboni, A.; Tamburini, B.; Rossi, T.; Donati, D. Tarzia, G.; Gaviraghi, G.; in "*Recent Advances in the Chemistry of Anti-Infetive Agents*" pag. 21, Ed. by Bentley, P.H.; Ponsford, R.; The Royal Society of Chemistry, **1993**

8) a) Perboni, A.; Bismara, C.; Pentassuglia, G. *Eur. Pat. Appl.* 466,509 (C07D 205/08). July 12, **1991**. b) Rossi, T.; Biondi, S.; Contini, S; Thomas, R.J.; Marchioro, C. *J. Am. Chem. Soc.* **1995**, *117*, 9604.

9) Iranpoor, N.; Mohammadpour Baltork, I. *Synth. Commun.* **1990**, *20*, 2789.

10) Minimal inhibitory concentrations (MIC) were determined according to the procedures recommended by NCCLS for aerobes (M7-A2, **10**, N8) and anaerobes (M11-A2, **10**, N 15).
Mueller Hinton broth (MHB), MHB supplemented with 5% of bovine serum and Schadler broth were used as test medium for aerobes, *S. pneumoniae* and anaerobes, respectively. The final bacterial inoculum was 10^5 CFU/ml.
The MIC was defined as the lowest drug concentration that resulted in no visible growth after 20 hours for aerobes and 48 hours for anaerobes of incubation at 37°C .
National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard. NCCLS M7-A2, **10**, N 8, Villanova, PA, USA.
National Committee for Clinical Laboratory Standards. 1990. Methods for antimicrobial susceptibility of anaerobic bacteria. Approved Standard. NCCLS M11-A2, **10**, N 15, Villanova, PA, USA.

(*Received in Belgium* 17 *May* 1996; *accepted* 26 *July* 1996)